Chintai, a Singapore-based blockchain company and a Singapore-licensed fund manager, Passion Venture Capital (PVC), have entered into a strategic cooperation agreement to promote the adoption of digital assets and real-world assets in Asia.
PVC, known for backing high-growth ventures in Asia’s expanding economies, sees the strategic cooperation as a timely move. CEO Davy J. Goh commented, “We have been working with Chintai for nearly three years and are impressed with their disciplined approach to building a regulated RWA tokenisation business since 2021”. He added, “We believe now is the opportune moment to deepen our collaboration with Chintai, because it will allow our portfolio companies and institutional partners a credible entry point into this high-growth sector”.
Chintai’s white-label platform provides end-to-end infrastructure for tokenising regulated assets, including bonds, real estate, and private funds, with automated on-chain compliance, governance, and secondary market trading capabilities. This solution enables financial institutions to expand product offerings, improve liquidity, and serve a new generation of investors.
David Packham, Chintai’s Founder and CEO, said, “We are honoured to move the relationship forward with Passion Venture Capital to the next level because this allows us to tap into the vast network that Davy and team have established over the past 20 years in Asia”. He added, “To date, we have tokenised millions of dollars of RWAs from our white labelling solution clients. This partnership continues to drive towards onboarding more assets in the near term”.
To ensure the business can scale rapidly, plans are in place to structure tokenised high-yield and liquid tokens, including high-yield asset-backed funds, high-yield private credit funds, mezzanine financing, pre-IPO and delisting financing, and investments in BioTech and MedTech sectors.
Chintai and PVC aim to become the bridge between traditional finance and regulated blockchain infrastructure for Asia’s capital markets. This strategic cooperation builds on a Memorandum of Understanding (MoU) signed in 2023 and an investor engagement event on the Passion BioTech and MedTech Global Fund.
